Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

David Aguilar, Samuel Z. Goldhaber, Daniel J. Gans, Andrew S. Levey, Jerome G. Porush, Julia B. Lewis, Jean Lucien Rouleau, Tomas Berl, Edmund J. Lewis, Marc A. Pfeffer

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.

Original languageEnglish
Pages (from-to)337-339
Number of pages3
JournalAmerican Journal of Cardiology
Volume94
Issue number3
DOIs
StatePublished - Aug 1 2004

Bibliographical note

Funding Information:
The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy'. Together they form a unique fingerprint.

Cite this